I worked at 23andMe during its collapse. Here’s what the next consumer-genomics giant needs to understand

23andMe, a consumer genomics company, is set to be acquired by Regeneron Pharmaceuticals after filing for bankruptcy, highlighting key challenges in the consumer genomics space. According to a genetic counselor's analysis, 23andMe's struggles stemmed from underestimating the need for clinical partnerships, a one-time revenue model, and the broader issue of governing health data outside traditional healthcare frameworks, rather than its lack of HIPAA compliance. The acquisition raises concerns about the future use of 23andMe's vast genetic database, particularly regarding data consent, equitable access to resulting drugs, and the need for greater transparency and public oversight in the use of consumer health data.

Analysis

The bankruptcy of 23andMe and its pending acquisition by Regeneron Pharmaceuticals (REGN) for its substantial assets, including a genetic database from approximately 12 million customers, marks a significant inflection point for the consumer genomics sector. The company's failure, despite its mission to empower individuals with genetic information, is attributed not to its non-HIPAA-compliant status—a deliberate design choice—but rather to fundamental strategic missteps. These include an underestimation of the critical need for deep, sustained partnerships with clinicians to ensure proper interpretation and application of genetic data, and a business model reliant on one-time purchases that proved unsustainable against platforms offering continuous engagement. 23andMe's approach, prioritizing rapid consumer expansion and research partnerships over clinical integration, led to a knowledge gap among both consumers and healthcare providers, hindering widespread adoption and trust. The company also launched into a market lacking the necessary regulatory and clinical infrastructure to fully support direct-to-consumer genetic testing. Regeneron's acquisition, with a backup bid from an entity led by 23andMe's co-founder, raises pivotal questions regarding the future use of the extensive consumer data, including consent, equitable access to potential drugs developed from this data, and the need for enhanced transparency and public oversight beyond current frameworks like HIPAA. The situation underscores a broader societal challenge in defining, governing, and trusting health information in an era of digital health platforms operating outside traditional healthcare boundaries.

Key Decisions for Investors

• Investors in Regeneron (REGN) should assess the strategic value of 23andMe's genetic database for accelerating drug development, while also monitoring potential reputational and regulatory risks associated with data privacy, consent, and the ethical use of such a large dataset.
• For those invested in or considering the consumer genomics and digital health sectors, 23andMe's downfall highlights the imperative for companies to establish sustainable recurring revenue models, foster deep clinical integration, and proactively address data governance and ethical concerns to build long-term viability and trust.
• Anticipate heightened regulatory scrutiny and evolving governance frameworks for consumer health data; companies demonstrating robust data protection, transparent usage policies, and strong clinician engagement will likely be better positioned for future success.
• Consider the precedent set by this acquisition regarding the valuation and potential repurposing of large-scale consumer health datasets, which may influence future M&A activity and strategic partnerships in the biotech and digital health industries.